Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $25.25.
Several brokerages have weighed in on AQXP. BidaskClub upgraded shares of Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 price target on shares of Aquinox Pharmaceuticals in a research report on Tuesday, November 21st. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th.
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.33 on Tuesday, reaching $14.98. 130,600 shares of the company’s stock traded hands, compared to its average volume of 112,704. Aquinox Pharmaceuticals has a one year low of $10.02 and a one year high of $19.97. The firm has a market capitalization of $359.25, a price-to-earnings ratio of -7.76 and a beta of -15.98.
WARNING: “Aquinox Pharmaceuticals Inc (AQXP) Given Average Rating of “Hold” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/aquinox-pharmaceuticals-inc-aqxp-given-average-rating-of-hold-by-analysts.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.